One out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading up 217 points (1.3%) at 16,418 as of Friday, Sept. 25, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,782 issues advancing vs. 1,190 declining with 158 unchanged.

The Drugs industry currently sits down 2.9% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

bluebird bio

(

BLUE

), down 9.0%,

Alnylam Pharmaceuticals

(

ALNY

), down 7.0%,

Medivation

(

MDVN

), down 5.8%,

Incyte

(

INCY

), down 2.7% and

Illumina

(

ILMN

), down 2.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

AstraZeneca

(

AZN

) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.40 (1.2%) to $32.85 on average volume. Thus far, 1.4 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $32.72-$33.01 after having opened the day at $32.89 as compared to the previous trading day's close of $32.45.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. AstraZeneca has a market cap of $81.7 billion and is part of the health care sector. The company has a P/E ratio of 31.7, above the S&P 500 P/E ratio of 24.3. Shares are down 7.8% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

GlaxoSmithKline

(

GSK

) is up $0.33 (0.8%) to $39.12 on light volume. Thus far, 1.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $39.03-$39.45 after having opened the day at $39.40 as compared to the previous trading day's close of $38.79.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $84.3 billion and is part of the health care sector. The company has a P/E ratio of 13.3, below the S&P 500 P/E ratio of 24.3. Shares are down 9.2% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

GlaxoSmithKline

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

GlaxoSmithKline Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Novartis

(

NVS

) is up $1.47 (1.6%) to $93.27 on average volume. Thus far, 1.2 million shares of Novartis exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $93.25-$94.02 after having opened the day at $93.90 as compared to the previous trading day's close of $91.80.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis has a market cap of $223.2 billion and is part of the health care sector. The company has a P/E ratio of 25.0, above the S&P 500 P/E ratio of 24.3. Shares are down 0.9% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts who rate Novartis a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Novartis

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Novartis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).